- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01267331
Cell Therapy in Patients With Chronic Ischemic Heart Disease Undergoing Cardiac Surgery
A Prospective,Randomized, Placebo-Controlled Study of Intramyocardial Injection of Autologous Bone-Marrow Mononuclear Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery
Study Overview
Status
Intervention / Treatment
Detailed Description
Severe ischemic heart disease remains a clinical challenge; many patients have undergone surgical myocardial revascularization procedures, but still remain symptomatic despite optimal medical therapy. Cell therapy with autologous bone marrow-derived cells (BMC) is a novel therapeutic strategy being tested for surgical treatment in patients with severe, chronic ischemic heart disease.
This research study is being performed to find out more information about the safety, feasibility, and efficacy of direct intramyocardial injection of autologous BMC on the myocardial perfusion and left ventricular function as an adjunctive therapy (compared to placebo) in patients undergoing coronary artery bypass surgery (CABG). The heart function evaluations will be performed by electrocardiogram, echocardiogram, and cMRI at baseline and during 6 months follow-up.
The secondary objective of this study is to assess the effect of intramyocardial injection of autologous BMC on functional class (angina/heart failure), global and cardiovascular mortality, and major adverse cardiac events after undergoing coronary artery bypass surgery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Changqing Gao, MD
- Phone Number: +8601066938035
- Email: gaochq301@yahoo.com
Study Contact Backup
- Name: Lin Zhang, MD
- Phone Number: +8601066938336
- Email: drzhanglin@gmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Recruiting
- Chinese PLA General Hospital
-
Principal Investigator:
- Wang Rong, MD
-
Principal Investigator:
- Zhang Lin, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 75 years.
- Scheduled to undergo CABG.
- At least 3 months since last episode of myocardial infarction.
- Echocardiogram-assessed LVEF between 15 and 40% (Simpson's rule).
- Abnormal wall motion of at least one segment due to prior myocardial infarction shown by echocardiography or left ventriculography.
- Abnormal myocardial perfusion in infarcted area by SPECT.
- Willingness to participate and ability to provide written informed consent.
Exclusion Criteria:
- Contraindications to magnetic resonance imaging.
- Need for urgent or emergent revascularization.
- Severe valvular heart disease.
- Confirmed myocardial infarction within 14 days, and/or rising cardiac biomarker proteins (i.e. troponin), and/or worsening ECG changes.
- Prior cardiac surgery.
- Stroke within 3 months prior to CABG.
- Immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)
- Severe chronic renal insufficiency (serum creatinine ≥ 200 mmol/dl or need for dialysis), liver disease, (diagnosis of cirrhosis, chronic hepatitis, or elevation of serum transaminases ≥3 times the upper limit of normal), cerebrovascular disease requiring concomitant carotid endarterectomy, peripheral arterial disease (claudication as the primary factor limiting activity), active non-dermatological malignancy requiring on-going treatment, or any other condition that would place the patient at increased risk for complications in the judgment of the attending cardiologist or cardiac surgeon
- Hemoglobin less than 10g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3
- Active infection, with a temperature greater than 37.5°C within 48 hrs prior to surgery and an unexplained white blood cell count in excess of 10,000/mm3
- Significant cognitive impairment.
- Any condition associated with a life expectancy of less than 6 months.
- Participation in other studies.
- Positive laboratory test results for HIV, HBC, and HCV.
- Pregnant woman.
- Inability or unwillingness to provide written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: stem cells injection
Direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG
|
Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
Other Names:
|
Placebo Comparator: palcebo intramyocardial injection
Direct intramyocardial injection of placebo containing saline and 5% human serum albumin during CABG.
|
Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
major adverse cardiac events
Time Frame: 6 months
|
Freedom from Major Adverse Cardiac Event: cardiac death, myocardial infarction, repeat coronary bypass grafting or percutaneous intervention of bypassed artery
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
left ventricular function
Time Frame: 6 months
|
Globlal function,regional myocardial perfusion and function assessed by magnetic resonance iamge and echocardiogram
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Gao Changqing, MD, Chinese PLA General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006AA02A104
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Left Ventricular Dysfunction
-
Berlin Heart, IncUnknownSevere Isolated Left Ventricular Dysfunction | Severe Biventricular Dysfunction
-
Lawson Health Research InstituteMedtronicTerminatedHeart Failure, Left Ventricular DysfunctionCanada
-
Berlin Heals GmbHRecruitingSystolic Left Ventricular DysfunctionCroatia, Serbia, Bosnia and Herzegovina
-
Berlin Heals GmbHRecruitingSystolic Left Ventricular DysfunctionSwitzerland, Croatia, Germany, Spain, Serbia, Bosnia and Herzegovina, Bulgaria, Greece, North Macedonia, Poland, Czechia
-
M.D. Anderson Cancer CenterCompletedHeart Failure | Cancer Treatment Induced Left Ventricular DysfunctionUnited States
-
AstraZenecaCompletedLeft Ventricle FunctionSweden
-
National Defense Medical Center, TaiwanRecruitingLeft Ventricular Systolic Dysfunction (Disorder)Taiwan
-
University of LeedsCompletedLeft Ventricular Function Systolic DysfunctionUnited Kingdom
-
University Hospital DubravaUnknownRight Ventricular Dysfunction | Left Ventricular Dysfunction | Biventricular FailureCroatia
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR)Unknown
Clinical Trials on bone marrow mononuclear cells injection
-
Nantes University HospitalCompleted
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHeart Failure, CongestiveUnited States
-
AldagenCompletedPeripheral Arterial Disease | Peripheral Vascular Disease | Critical Limb IschemiaUnited States
-
TotipotentSC Scientific Product Pvt. Ltd.Thermogenesis Corp.CompletedCritical Limb IschemiaIndia
-
Xijing HospitalUnknownMyocardial InfarctionChina
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedChronic Myocardial IschemiaSpain
-
IRCCS San RaffaeleSuspended
-
Vinmec Healthcare SystemCompleted
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedIschemic StrokeUnited States